News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Durata Therapeutics, Inc. Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI


12/11/2012 10:41:07 AM

CHICAGO--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced preliminary, top-line results for its DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES